Exenatide: Effect of injection time on postprandial glucose in patients with Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue 3, 2006, Pages 240-245

  Linnebjerg, H ^a   Kothare, P A ^a   Skrivanek, Z ^a   De La Pena A ^a   Atkins, M ^a   Ernest II, C S ^a   Trautmann, M E ^b  

^a ELI LILLY AND COMPANY   (United States)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Diabetes; Exenatide; Glucose dependent; Incretin; Postprandial

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIZZINESS; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MEAL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; VOMITING;

AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; VENOMS;

EID: 33645072735     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01800.x     Document Type: Article

References (20)

1. Drucker DJ Biological actions and therapeutic potential of the glucagon-like peptides Gastroenterology 2002 122 531 544
2. Verdich C Flint A Gutzwiller JP Naslund E Beglinger C Hellstrom PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans J Clin Endocrinol Metab 2001 86 4382 4389
3. Kjems LL Holst JJ Volund A Madsbad S The influence of GLP-1 on glucose-stimulated insulin secretion: effects on {beta}-cell sensitivity in type 2 and nondiabetic subjects Diabetes 2003 52 380 386
4. Egan JM Bulotta A Hui H Perfetti R GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells Diabetes Metab Res Rev 2003 19 115 123
5. Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 952 957
6. Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2004 359 824 830
7. Thorens B Porret A Buhler L Deng SP Morel P Widmann C Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 1993 42 1678 1682
8. Kolterman OG Buse JB Fineman MS Gaines E Heintz S Bicsak TA et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 2003 88 3082 3089
9. Edwards CM Stanley SA Davis R Brynes AE Frost GS Leighton JS et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 2001 281 E155 E161
10. Parkes D Jodka C Smith P Nayak S Rinehart L Gingerich R Chen K Young A Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1 Drug Dev Res 2001 53 260 267
11. Kolterman O Kim D Shen L Ruggles JA Nielsen LL Fineman MS et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am J Health Syst Pharmacy 2005 62 173 1 81
12. DeFronzo R Ratner R Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 100
13. Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes mellitus Diabetes Care 2004 27 2628 2635
14. Kendall DM Riddle MC Rosenstock J Zhuang D Kim DD Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 91
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 837 853
16. Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 2003 26 2929 2940
17. Nielsen LL Young AA Parkes DG Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul Pept 2004 117 77 88
18. Dimitriadis GD Gerich JE Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus Diabetes Care 1983 6 374 7
19. Hermann LS Optimising therapy for insulin-treated type 2 diabetes mellitus Drugs Aging 2000 17 283 294
20. Degn KB Brock B Juhl CB Djurhus CB Grubert J Kim D et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia Diabetes 2004 53 2397 2403